COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The SOLID Platelet Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03712618
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : January 31, 2020
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC)

Brief Summary:


Platelets are cell fragments in the blood that help it clot. Some people get very low platelet counts during a disease or treatment. Low platelet counts can cause severe bleeding. Some people are not helped by platelet transfusions at the standard transfusion rate. This is called platelet transfusion refractoriness (PTR). Researchers want to learn more about transfusing platelets so they can make transfusions more effective.


To study the effects of transfusing platelets more slowly than the standard rate. To obtain data to improve the effectiveness of platelet transfusions in people with PTR and decrease the risk of bleeding in some people.


Adults ages 18-100 who have very low platelet counts requiring platelet transfusion, and have evidence of PTR


Participants will be screened with a review their recent NIH medical records. They will have blood drawn.

Participants will have up to three 12-hour treatment blocks. They can have only one block per day. During each block, they will have 2 platelet transfusions in those 12 hours.

One transfusion will take place over 1 hour (SHORT infusion). The other will take place over 4 hours (LONG infusion).

Participants will be randomly put in 1 of 2 treatment groups. This will dictate whether they get the SHORT or LONG infusion first.

Participants will have blood drawn:

  • When they enroll
  • Right before each transfusion
  • 2, 4, and 6 hours after each transfusion

Each blood draw will consist of a complete blood count. Smaller tubes that require only small amounts of blood will be used to minimize the amount of blood drawn.


Condition or disease Intervention/treatment Phase
Platelet Transfusion Refractoriness (PTR) Thrombocytopenia Other: Platelet Transfusion - LONG Platelet Transfusion Other: Platelet Transfusion - SHORT Platelet Transfusion Phase 2

Detailed Description:
Platelet transfusion can be a life-saving procedure in preventing or treating serious bleeding in patients who have low and/or dysfunctional platelets. Treatment of blood cancer and other blood diseases, as well as bone marrow transplantation, is not possible without platelet transfusion support. Unfortunately, 15- 25% of chronically transfused patients platelet counts will stop responding to these transfusions, putting them at risk for serious bleeding complications. The development of HLA antibodies is responsible for 4- 8% of this platelet transfusion refractoriness. The presence of HLA antibodies is a clinical complication that is generally managed by the selection of products that are negative for the antigens for which the patient has antibodies. Often, for patients with chronic and ongoing need, this selection is facilitated by targeted recruitment of donors with known HLA types (i.e., types that lack antigens cognate to the patient s known antibodies and are thus predicted to be compatible). However, for very broadly HLA- alloimmunized patients, compatible products may be exceedingly scarce or completely unavailable, precluding the ability to consistently provide products the patient will likely increment from. This research protocol is designed to evaluate the efficacy of a 4-HOUR continuous infusion of single donor, apheresis platelets in overcoming both alloimmune-mediated and non-alloimmune-mediated platelet refractoriness. We hypothesize that when we transfuse patients over a long duration, who have platelet refractoriness, the platelet counts will increase to higher numbers for an extended period of time in the peri-transfusion period when compared to shorter transfusion intervals.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Short or Long Infusion Duration of Platelets: The SOLID Platelet Study
Actual Study Start Date : June 10, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Group A
Group A: Long Transfusion followed by Short Transfusion in the first block
Other: Platelet Transfusion - LONG Platelet Transfusion
Platelets Transfused over 4-HOURS

Other: Platelet Transfusion - SHORT Platelet Transfusion
Platelets Transfused within 60-minutes

Active Comparator: Group B
Group B: Short Transfusion followed by Long Transfusion in the first block
Other: Platelet Transfusion - LONG Platelet Transfusion
Platelets Transfused over 4-HOURS

Other: Platelet Transfusion - SHORT Platelet Transfusion
Platelets Transfused within 60-minutes

Primary Outcome Measures :
  1. Adusted platelet measurement area under the curve (AUC) [ Time Frame: 3-years ]
    To evaluate efficacy of continuous platelet transfusions in overcoming platelet transfusion refractoriness, including HLA-alloimmune-mediated refractoriness, in patients with severe thrombocytopenia.

Secondary Outcome Measures :
  1. Impact on bleeding [ Time Frame: 3-years ]
    To characterize the efficacy of continuous platelet infusion on bleeding outcomes, as measured during the peri-transfusion period by daily hemostatic assessments using the World Health Organization (WHO) bleeding scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Ability to comprehend the investigational nature of the study and provide informed consent
  • Thrombocytopenia

    • Causes of thrombocytopenia may be due to:

      1. Congenital causes
      2. Bone marrow
      3. Hematologic malignancies
      4. Treatment related
    • Thrombocytopenia is generally defined as one of the following:

      1. <10K/uL without bleeding
      2. <20K/uL for "complicated prophylaxis" in patient s determined to be at increased risk of bleeding or other complications
      3. <50K/uL with evidence of active bleeding, such as intracranial hemorrhage, GI bleeding, pulmonary hemorrhage, uncontrolled epistaxis, hematuria.

        The treating provider may change the platelet transfusion threshold based on the clinical circumstance, patient population, and/or concurrent primary protocol considerations - similar to the PLADO study.

  • Diagnosed with PTR, characterized by the following:

    • Lack of adequate post-transfusion platelet count increment, defined by, CCI <5000/ul at 10-60 min after each of at least 2 consecutive platelet transfusions
    • Presence of anti-HLA class 1 type A and/or type B antibody, in the setting of PTR, as defined above, constitutes the HLA alloimmune-mediated subtype of PTR. Presence of one or more HPA antibodies in the setting of PTR, as defined above,constitutes the HPA alloimmune-mediated subtype of PTR. Failure to detect HLA or HPA antibodies will be categorized as non-alloimmune-mediated PTR. .


  • Less than 18-years-old
  • Lack of ability to obtain informed consent
  • Pregnant female
  • Presence of ITP/autoimmune thrombocytopenia
  • Immune platelet refractoriness responsive to treatment with IVIg or eculizumab, or other immunosuppressive therapy within the 3 preceding months. This is based on the wide variation in the duration therapeutic antibodies, with the upper limit frequently cited as 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03712618

Layout table for location contacts
Contact: Sarah Pogue, R.N. (301) 435-2432

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
Layout table for investigator information
Principal Investigator: Willy A Flegel, M.D. National Institutes of Health Clinical Center (CC)
Additional Information:
Layout table for additonal information
Responsible Party: National Institutes of Health Clinical Center (CC) Identifier: NCT03712618    
Other Study ID Numbers: 190005
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: January 31, 2020
Last Verified: January 28, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC):
Platelet Transfusion Refractoriness
Continuous Platelet Transfusion
Additional relevant MeSH terms:
Layout table for MeSH terms
Blood Platelet Disorders
Hematologic Diseases